Flagship Pioneering Inc. continued to hold its position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,806,656 shares of the company’s stock at the end of the second quarter. Syros Pharmaceuticals makes up about 27.3% of Flagship Pioneering Inc.’s holdings, making the stock its 2nd largest position. Flagship Pioneering Inc. owned approximately 0.18% of Syros Pharmaceuticals worth $77,339,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in SYRS. Redmile Group LLC increased its position in shares of Syros Pharmaceuticals by 0.5% in the first quarter. Redmile Group LLC now owns 952,740 shares of the company’s stock valued at $15,177,000 after buying an additional 4,300 shares in the last quarter. Schwab Charles Investment Management Inc. purchased a new position in shares of Syros Pharmaceuticals during the second quarter valued at about $343,000. Wells Fargo & Company MN purchased a new position in shares of Syros Pharmaceuticals during the first quarter valued at about $225,000. Rhumbline Advisers purchased a new position in shares of Syros Pharmaceuticals during the second quarter valued at about $198,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Syros Pharmaceuticals during the first quarter valued at about $185,000. 49.45% of the stock is owned by hedge funds and other institutional investors.

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) opened at 21.81 on Friday. The firm has a 50-day moving average of $19.45 and a 200 day moving average of $15.40. The firm’s market cap is $572.73 million. Syros Pharmaceuticals, Inc. has a 52-week low of $8.50 and a 52-week high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.03. On average, equities analysts predict that Syros Pharmaceuticals, Inc. will post ($2.09) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/08/13/flagship-pioneering-inc-has-77339000-stake-in-syros-pharmaceuticals-inc-nasdaqsyrs.html.

Several equities research analysts have weighed in on the stock. ValuEngine upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Zacks Investment Research cut shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Cowen and Company restated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. JMP Securities cut shares of Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday. Finally, Wedbush restated an “outperform” rating and issued a $22.84 price objective (down previously from $25.00) on shares of Syros Pharmaceuticals in a research report on Thursday. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $20.81.

In other news, Director Richard A. Young sold 3,282 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $22.09, for a total transaction of $72,499.38. Following the completion of the sale, the director now owns 423,383 shares of the company’s stock, valued at approximately $9,352,530.47. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Eric R. Olson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $23.59, for a total transaction of $58,975.00. Following the sale, the insider now directly owns 2,500 shares of the company’s stock, valued at approximately $58,975. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,282 shares of company stock valued at $404,599.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Want to see what other hedge funds are holding SYRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS).

Institutional Ownership by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.